Ingelvac PRRS^® MLV, a leading modified-live porcine reproductive and respiratory syndrome (PRRS) vaccine, has been trusted for over 25 years to protect the swine industry against reproductive and respiratory symptoms of PRRSv.    

INGELVAC PRRS MLV is a modified-live PRRS vaccine that is proven safe in pigs as well as gilts and sows at any stage of production in PRRS-positive herds. It provides cross-protection against heterologous challenge (including Lineage 1 viruses), and has been shown to significantly reduce reproductive failure and respiratory disease due to PRRS virus.  

For over 25 years, Boehringer Ingelheim has been helping the industry combat PRRS. With INGELVAC PRRS vaccines, technical expertise, collaborative research and diagnostic advancements, we are working with veterinarians and producers to win the battles against this challenging disease. 

• Demonstrated Heterologous Cross-Protection Ingelvac PRRS^® MLV has demonstrated significant cross-protection against the most current relevant heterologous wild-type PRRS virus strains and continues to be evaluated in order to provide you with the most up-to-date information.

• Whole-Herd Approach (Use at any stage of production)  INGELVAC PRRS MLV is the only vaccine that has demonstrated proven efficacy and safety in all stages and phases of production. So, mass vaccination or population-based protocols are recommended for building and maintaining whole-herd immunity.  

• Consistent and Repeatable Direct and Indirect Benefits  

 

DIRECT BENEFIT: Multiple controlled and field-based studies have demonstrated that INGELVAC PRRS MLV mitigates the consequences of infection; it reduces clinical disease and provides biologic benefit, thus improving health and performance. 

 

INDIRECT BENEFIT: Studies have also shown vaccination with INGELVAC PRRS MLV contributes to reduced magnitude and duration of viremia, as well as reduced shedding of wild-type PRRSV within and from vaccinated populations, leading to a reduction in the challenge risk and infection pressure within and between vaccinated herds and populations.  

 

• Complete PRDC Protocol (Most extensive PRRS vaccine line)  INGELVAC PRRS MLV is the only PRRS vaccine licensed by the USDA for use in the widest range of combinations (for example: 3FLEX^®, FLEXcircoPRRS^® and FLEXmycoPRRS^®) to best meet the needs of your protocol and operation. 

Ingelvac PRRS^® MLV utilizes the same intramuscular (IM) dose size (2 mL) for pigs, adult breeding-age or pregnant females.  

Pigs, gilts and sows: INGELVAC PRRS MLV is recommended for use in healthy susceptible swine in PRRS virus-positive herds, according to label direction. Using aseptic technique, administer a single 2-mL dose intramuscularly for the reproductive and respiratory form of the disease. The duration of immunity is throughout the finishing or gestation period, or at least four months post vaccination.  

The vaccine can be used at any stage of production. Revaccination of the whole herd can occur every three to four months or as directed by your veterinarian.  

DO NOT VACCINATE BOARS.  

Administration

Image

Rehydrate the vaccine by adding a portion of the contents of the accompanying diluent to the vaccine vial. Shake well and transfer the reconstituted suspension back into the diluent bottle, mix with the remaining diluent to complete to the total volume of the diluent bottle. Shake well and use immediately. See insert for complete information.  

Learn more about mixing INGELVAC PRRS vaccines.

INGELVAC PRRS MLV Safety Data Sheet (SDS) 

• For Swine use only.   
• Ingelvac PRRS^® MLV: Do not vaccinate boars.   
• Store in dark at 35-45F (2-7C). Do not freeze. Use entire contents when first opened. In case of anaphylactic reaction, epinephrine is symptomatic treatment. Do not vaccinate with 21 days before slaughter.